Olodanrigan (sodium)

• Description:

  Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4].

• Product Name Alternative:

  EMA401 (sodium) ; PD-126055 (sodium)

• UNSPSC:

  12352005

• Target:

  Angiotensin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Endocrinology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/olodanrigan-sodium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C ([C@H]1N (C (C (C2=CC=CC=C2) C3=CC=CC=C3) =O) CC4=C (C (OCC5=CC=CC=C5) =C (OC) C=C4) C1) O[Na]

• Molecular Formula:

  C32H28NNaO5

• Molecular Weight:

  529.56

• References & Citations:

  [1]Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383 (9929) :1637-47.|[2]Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.|[3]Suguru Koyama, et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  AT2 Receptor

• CAS Number:

  1316755-17-5